Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.

With mice, researchers showed that experimentally induced lack of blood flow in the brain epigenetically reprograms astrocytes into brain stem cells, which in turn can give rise to nerve progenitor cells. This discovery shows that astrocytes could potentially be used in regenerative medicine to replace damaged nerve cells.

Innovation for sustainable plastic packaging - 04/09/2024

Liquid Plug & Play: eco-designed plastic packaging – not just for ultrasound gel

In the healthcare industry tons of consumables such as ultrasound gel go to waste because packaging can’t be completely emptied. An invention called Liquid Plug & Play could offer a solution for the future. This innovation, which consists of a reusable outer shell and a disposable product pouch for viscous substances, can be completely emptied. It also prevents cross-contamination and offers many other benefits.

Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.

BioRegio STERN Management GmbH was today presented with an award at the Innovation Day for SMEs held by Germany’s Federal Ministry for Economic Affairs and Climate Action. Its “biohymed” project was named the year’s best innovation network under the Central Innovation Programme for SMEs (ZIM).

In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.

Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

Epifadin from the nasal microbiome - 28/03/2024

From the nose: novel antibiotic substance discovered

Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.

Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).

The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.

Health Data Futures project - 11/01/2024

Creating a network of trust

In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.

Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.

For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

Augmented reality for visual orientation - 15/11/2023

Fall prevention with the help of balance-enhancing AR glasses

As we age, our eyesight deteriorates and we have increasing difficulties with orientation. This can lead to balance problems and fatal falls. A team led by Dr. Lorenz Assländer from the University of Konstanz is currently developing a prototype of augmented reality (AR) glasses that use superimposed patterns to facilitate visual orientation in space, thereby helping to improve balance control and prevent falls.

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.

Project BlindZero - 03/08/2023

Hope for patients with eye diseases: human cornea from 3D printers

Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.